Alpha-0261

Phase 1Small molecule

Alpha-0261 is one of 4 small molecule programs targeting Chronic Spontaneous Urticaria (CSU). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Spontaneous Urticaria (CSU)Not yet recruiting

Chronic Spontaneous Urticaria (CSU)Phase 1

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Chronic Spontaneous Urticaria (CSU)

#DrugCompanyPhaseTrials

Rhapsido

Novartis

Phase 3

1 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

1 3

Alpha-0261

AAlphaMol Science Ltd. (Shanghai)

Phase 1

1 4

TLL-018

HHangzhou Highlightll Pharmaceutical Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Chronic Spontaneous Urticaria (CSU)

NCT07684560

Clinical

Trials by Indication[1]

Chronic Spontaneous Urticaria (CSU)1 trial

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Oral Doses of Alpha-0261 Tablets in Patients With Chronic Spontaneous Urticaria, and the Effect of Food in Healthy Participants.

Not yet recruiting·AAlphaMol Science Ltd. (Shanghai)·Phase 1·NCT07684560·48 enrolled

Unspecified1 trial

A Randomized, Double-blind, Placebo-Controlled, Dose-Escalation, Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Oral Administration of Alpha-0261 Tablets in Adult Healthy Participants

Completed·AAlphaMol Science Ltd. (Shanghai)·Phase 1·NCT07279636·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Alpha-0261. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alpha-0261 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alpha-0261. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AlphaMol Science Ltd. (Shanghai) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAlphaMol Science Ltd. (Shanghai)

Alpha-0261

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Chronic Spontaneous Urticaria (CSU)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News